Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Learn more about:
Related Clinical Trial
Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Official Title

Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label

Brief Summary

      The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and
      0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the
      treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex
      (TSC).
    

Detailed Description

      This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed
      to assess the safety and efficacy of topically-applied sirolimus for the treatment of
      cutaneous angiofibromas in pediatric subjects with TSC. Approximately 45 subjects will be
      enrolled at investigational sites in the United States (US) and China, though other countries
      may be added in the future. Approximately 45 subjects who meet the study entry criteria will
      randomly be assigned in a 1:1:1 ratio to receive 1 of 3 treatments: sirolimus 0.2% ointment,
      sirolimus 0.4% ointment, or placebo ointment. The randomization is stratified by site.
      Subjects, or a parent/guardian, will apply the study medication topically to the cutaneous
      angiofibromas on the face once daily at night before going to bed for 12 weeks. Subjects who
      complete the double-blind phase of the study, with an overall compliance rate >80% as
      determined by the dosing diary, will be offered entry into an open-label period for an
      additional 12 weeks.

      The maximum study duration for each subject will be approximately 30 weeks and includes a
      screening period of up to 4 weeks, a blinded treatment period of 12 weeks, optional
      open-label period of 12 weeks, and a follow-up period of 2 weeks.

      An interim analysis will be performed when all subjects have completed the double-blind phase
      (Visit 5 - Week 12). The data will be unblinded to assess for efficacy and results reported.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

The proportion of subjects with a clinical response of treatment success.

Secondary Outcome

 The proportion of subjects with at least 30% improvement at Week 12 as compared to Baseline in the Facial Angiofibromas Severity Index (FASI) score.

Condition

Angiofibroma of Face

Intervention

Sirolimus 0.2%

Study Arms / Comparison Groups

 Arm 1
Description:  Sirolimus 0.2% ointment applied topically hs x 12 weeks

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

45

Start Date

April 12, 2017

Completion Date

April 2022

Primary Completion Date

December 2021

Eligibility Criteria

        Inclusion Criteria:

          1. Generally healthy males or non-pregnant females aged 2 to 21 years, inclusive, at the
             time of screening.

          2. Diagnosis of TSC with visible facial angiofibromas of at least grade 3 up to grade 5,
             inclusive, based on the IGA.

          3. Subjects with 3 or more isolated, measurable lesions of facial angiofibroma, with
             color grading score ≥2 for each of the 3 lesions.

          4. Females of childbearing potential must have a negative urine pregnancy test (or a
             negative serum pregnancy test if a urine pregnancy test cannot be obtained) (For
             China, different pregnancy test would be followed) and if sexually active or become
             sexually active during the study, must agree to use an effective form of birth control
             for the duration of the study. Females using oral contraceptives must also use a
             barrier method of contraception during the study. Sexually active male subjects and/or
             their female partners should also use appropriate contraception.

             Effective contraception is defined as follows:

               -  Oral/implant/injectable/transdermal/estrogenic vaginal ring contraceptives,
                  intrauterine device, condom with spermicide, diaphragm with spermicide.

               -  Abstinence or partner's vasectomy are acceptable if the female agrees to
                  implement one of the other acceptable methods of birth control if her partner
                  changes.

          5. The subject and/or their parent or guardian must be willing and able to provide
             written informed consent/assent.

          6. Willing and able to comply with all trial requirements.

          7. Subject or parent/guardian must be able to complete the subject self-assessment survey
             and subject diary in English or another language into which the documents have been
             officially translated.

          8. Subjects should be in good general health based on the subject's medical history,
             physical exam, and impression of the study doctor.

             Exclusion Criteria:

          9. Has any chronic or acute medical condition, that in the opinion of the investigator,
             may pose a risk to the safety of the subject during the trial period, or may interfere
             with the assessment of safety or efficacy in this trial.

         10. Has received oral therapy or topical therapy of an mTOR inhibitor (sirolimus,
             temsirolimus, or everolimus) within 1 month of Baseline or other dermatological
             treatment to facial angiofibromas within 1 month of baseline. (Sunscreen is expected
             to be used in this patient population and is not considered treatment.)

         11. Is currently receiving any form of immunosuppression therapy or has previously
             experienced significant immune dysfunction.

         12. Has a history of sensitivity to any component of the investigational product.

         13. Is pregnant, plans to become pregnant during the course of the study, or is
             breastfeeding.

         14. Has other dermatologic conditions, pigmentation, scarring, pigmented lesions or
             sunburn in the treatment area that would preclude or prevent adequate assessment of
             changes to their facial angiofibromas.

         15. Has facial hair (e.g., beard, sideburns, mustache) that could interfere with study
             assessments.

         16. Has had laser surgery or cryotherapy to facial angiofibromas within 6 months preceding
             study entry.

         17. Requires the use of any concomitant medication that, in the investigator's opinion,
             has the potential to cause an adverse effect when given with the investigational
             product or will interfere with the interpretation of the study results (see Section
             16.1 Appendix 1 for Potential Drug Interactions).

         18. Has participated in another clinical trial or received an investigational product
             within 3 months prior to screening.
      

Gender

All

Ages

2 Years - 21 Years

Accepts Healthy Volunteers

No

Contacts

Shoufeng Li, Ph.D, 732-652-9225, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT03363763

Organization ID

AUCTA-UAP006-PH2


Responsible Party

Sponsor

Study Sponsor

Aucta Pharmaceuticals, Inc


Study Sponsor

Shoufeng Li, Ph.D, Study Director, Aucta Pharmaceuticals, Inc


Verification Date

May 2021